Technology ID

Human Monoclonal Antibodies to Generate Chimeric Antigen Receptor (CAR) T-cells to Treat Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC).

Lead Inventor
Childs, Richard (NHLBI)
Chen, Long (NHLBI)
Cherkasova, Elena (NHLBI)
Research Materials
Therapeutic Areas
Development Stages
Pre-Clinical (in vitro)
Research Products
Lead IC

This technology includes six human monoclonal antibodies (mAbs) that target tumor antigens derived from the CT-RCC HERV-E (human endogenous retrovirus type E) to generate Chimeric Antigen Receptor (CAR) T cells to treat patients with advanced clear cell renal cell carcinoma (ccRCC). These mAbs were identified from Adagene Inc’s human antibody phage library, and data show that majority of these mAbs only bind to CT-RCC HERV-E+ ccRCC cells, which express TM but not CT-RCC HERV-E non-expressing ccRCC cells nor non-RCC cells. None of them showed non-specific binding to peripheral blood cells from healthy donors or human normal cell lines. Our data are consistent with the identification of several novel human mAbs that bind to the CT-RCC HERV-E Env TM with high specificity and no cross-activity. These mAbs have the potential to be used to generate CAR-T cells targeting HERV-E TM as a treatment for advanced ccRCC.

Commercial Applications
Treatment for renal cell carcinoma.

Competitive Advantages
  • First ever discovered mAbs targeting a highly specific antigen in ccRCC with minimal to no cross-activity.
  • These mAbs are human antibodies that won’t trigger human anti-idiotype antibody formation when used in treating kidney cancer patients, which is an advantage compared to mice mAbs or chimeric mAbs.
  • These mAbs are screened from patented human antibody phage library (Dynamic Precision Library Platform- Adagene INC) ensuring them to hit the unique epitopes of the target TMN protein, which would not be achieved by standard mAbs discovering methods.
  • CAR-T cells that would be derived from these mAbs would potentially be the first CAR -T therapy targeting an antigen restricted to ccRCC.
Licensing Contact:
Shmilovich, Michael